Gastrointestinal stromal tumors (GIST) have KIT or platelet-derived growth factor receptor α (PDGFRα) mutations affecting receptor tyrosine kinase activity and do not benefit from classic treatment regimens. Aims: The aim of this study was to review the algorithm that may be followed for the diagnosis and differential diagnosis in GISTs by investigating the histomorphological parameters and expression characteristics of classical immunohistochemical antibodies used in routine tests in addition to DOG1 expression. Study Design: Diagnostic accuracy study. Methods: We reevaluated the histological and immunohistochemical parameters of 37 GISTs. The standard immunohistochemical diagnosis and differential diagnosis panel antibodies (CD117, PDGFRα, CD34, vimentin, desmin, SMA, S-100, and Ki67) were studied on the tumor sections. We also used the popular marker DOG1 antibody with accepted sensitivity for GISTs in recent years and the PDGFRα immune marker for which the benefit in routine practice is discussed. Results: Classification according to progressive disease risk groups of the 37 cases revealed that 54% were in the high risk, 19% in the moderate risk, 16% in the low risk, 8% in the very low risk and 8% in the no risk group. Cytological atypia, necrosis, mucosal invasion and the Ki67 index were found to be related to the progressive disease risk groups of the tumors (p<0.05). Positive immunoreaction was observed with CD117 and PDGFRα in all GISTs in the study (100%). Positivity with the DOG1 antibody was found in 33 (89%) cases. CD34 was positive in 62% (23) of the cases. Conclusion: The CD117 antibody still plays a key role in GIST diagnosis. However, the use of DOG1 and PDGFRα antibodies combined with CD117 as sensitive markers can be beneficial.
Gastrointestinal stromal tumors (GISTs) are relatively rare but still the most common mesenchymal tumors of the gastrointestinal system (GIS). The importance of true diagnosis of GISTs has been emphasized due to the fact that they are a model in targeted treatment regimens and there are developments in treatment protocols currently in progress (1) .
Immunohistochemical (IHC) findings of GISTs published in the literature have been developed for the last 25 years. The first studies have focused on the expression of myoid and neural antigens, but the results were inconsistent. A hematopoietic stem cell determinant CD34 was subsequently tried and found to be expressed in most GISTs in all locations. It was concluded in recent years that immunoexpression of CD117 (c-kit) as an IHC marker of intestinal Cajal cells, which are the origin cells of GISTs, is a gold standard for final diagnosis in tumors, revealing locations and morphological findings that are consistent with GIST (1). However, CD117 expression has not been demonstrated in certain cases, especially PDGFRα mutant or wild types. The GIST1 (DOG1) antibody has therefore been added to the diagnostic panel as an alternative marker to accompany CD117 in the routine diagnostic algorithm for GISTs (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) .
The DOG1 gene is located on the CCND1-EMS1 loci of human chromosome 11q13 (12) (13) . This gene contains 26 exons and encodes a 960-amino-acid protein of approximately 114 Kb. Basic DNA sequence analyses have identified 8 transmembrane domains in this protein. Its function is not known, but the high number of transmembrane zones suggests that it acts as an ion channel (12, 14) . The gene product, known as TMEM16A (transmembrane protein 16A), was found to be a calcium-dependent chloride channel protein, consistent with the initial hypotheses, and was renamed anoctamin1 (ANO1) (1, (15) (16) (17) .
There are many articles which have discussed the correct diagnosis of gastrointestinal stromal tumors and their prognosis. After the evaluation of many parameters, the National Institutes of Health (NIH) published a consensus in 2002 based on morphological findings for use as a reference for the diagnosis and evaluation of the prognosis of GISTs (18) . Following the publication of this consensus, a couple of larger clinicopathological studies have been published by the Armed Forces Institute of Pathology (AFIP), which provide important information for understanding the biology of these tumors (1, 19, 20) . This risk stratification table is the current schema that is generally used in studies and clinical routine evaluations.
The aim of this study was to review the algorithm that may be followed for the diagnosis and differential diagnosis in GISTs by investigating the histomorphological parameters and expression characteristics of classical immunohistochemical antibodies used in routine tests in addition to DOG1 expression. 
MATERIALS AND METHODS

Patient selection and histopathological evaluation
Immunohistochemical scoring
Cytoplasmic immunoreaction over 10% of the evaluated slide was accepted as positive for vimentin, desmin, CD34, PDGFRα, SMA, and S-100. All cases were recorded as positive or negative. Various scoring methods have been used to evaluate the expression of CD117 and DOG1 in tissues in the literature (2, 4, 6, (21) (22) (23) (24) (25) . We used the following criteria for the evaluation of CD117 and DOG1 expression according to the extent of staining: 0-10% staining (negative), 10-50% staining (focal), and >50% staining (diffuse). The intensity of staining was classified as: (+) mild, (++) moderate, and (+++) strong (21) (22) (23) 4, 2015 staining; staining in 0-10% of the sample was accepted as negative, staining in 10-50% of the sample was accepted as focal positive, and staining in >50% of the sample was accepted as diffuse positive. The Ki67 antibody was studied on tissues with the highest mitotic index and the percentage of nuclear positivity in 1000 cells was determined.
Statistical analysis
Statistical analyses were performed in SPSS for Windows Version 16.0 (SPSS Inc., Chicago, IL, USA). After performing normality tests, Clinicopathological features were compared by risk groups, using Pearson Chi Square tests, Fisher's Exact test, Mann-Whitney U test and Kruskal-Wallis test. The correlation analysis of the antibody (CD117, DOG1, Ki67) expressions with risk groups was done by using Spearman Correlation Analysis. A p<0.05 was accepted as significant in all tests.
RESULTS
Clinical and histopathological examination
The 37 GIST cases making up the study group were reevaluated according to the risk categorization based on "the risk of progressive disease" (1, 18) . The clinicopathological characteristics are presented in Table 1 . The age distribution was 23-74 years. More than half of the cases were localized in the small intestine (51.4%). The tumor size varied between 0.6 and 24 cm (mean diameter 9.3 cm) (Table 2, Figure 1 ). (20 cases) and others (included no risk, very low risk, low risk, and moderate risk groups; 17 cases) as the low number of cases in certain groups otherwise prevented the use of a statistical method and statistically compared the clinicopathological features with these groups (Table 1) .
There was a statistically significant association between the tumor risk groups (according to high risk and all other risk groups) and mean tumor size (p=0.007), number of mitoses (p=0.000) cytological atypia (p=0.031), necrosis (p=0.033) and mucosal invasion (p=0.013), while no significant relationship was found with gender, age, bleeding and mucosal ulcer (Table 1) (Figure 2 ). A proportional relationship was present between presence of cytological atypia and number of mitoses (p=0.013) ( Table 3) .
No statistical comparison was made between the groups of progressive risk of disease and the tumor region, tumor size, cellularity, tumor cell type, adjacent tissue invasion, multifocality, recurrence or metastasis rate due to the inadequate number of cases.
Immunohistochemical findings
Positive immunoreaction with vimentin, CD117 and PDGFRα was observed in all cases. There was positive reaction for CD34 in 23 (62%) and SMA in 2 (5%) cases and for the S-100 antibody in 1 (3%) case. Desmin was negative in all cases (Table 4, Figure 3 ).
Comparing the number of mitoses with the staining pattern of CD117 in tumoral tissue showed that the mean number of mitoses in the cases with focal and/or weak CD117 positivity (31.40±22.07 in 5 cases) to be significantly higher than in the strong and diffuse cases (10.43±11.85 in 32 cases) (MannWhitney U test, p=0.038). Generally diffuse and strong cytoplasmic positive reaction with DOG1 was found in 33 (89%) cases (Figure 4 ). There was mild decrease in intensity and extent of DOG1 positivity with increasing risk group but this was not statistically significant (Fisher's exact test; p=0.367), (Table 5) .
When tumor risk groups and the Ki67 proliferation index were compared, the Ki67 ratio was over 10% in 60% of cases with high risks. A Ki67 proliferation index higher than 10% in the high risk group was found to be statistically significant (Pearson χ 2 ; p=0.003). 
DISCUSSION
Gastrointestinal stromal tumors have been previously described as tumors of the gastrointestinal system with mesenchymal character in which the origin could not be identified and the tumor did not respond to classic treatment; however, we are now able to identify and determine the origin of these tumors. The development of new-targeted treatment regimens could create models for molecular medicine by taking the biology of these tumors into account (11, 21, 22) . GISTs currently make up about 80% of mesenchymal tumors developing in the GIS (23). They constitute less than 1% of all gastrointestinal tumors (24) .
Although GISTs can be detected in all organs along the gastrointestinal (GI) tract with different biological behaviors, they are most commonly seen in the stomach (50-70%) and small intestine (20-40%) (11, (26) (27) (28) (29) . GISTs are less common in the rectum, esophagus, omentum and mesentery, with an incidence of 5-10% and in regions outside the GI tract with an incidence of <5% (30, 31) . The most common location in our cases was the small intestine (51.4%) followed by the stomach (29.7%). Many studies have reported anatomical localization as an independent prognostic factor in GISTs. GISTs located in the small intestine have a worse prognosis than those in the stomach with similar diameter and mitotic activity (19, 20) . 
TABLE 5. Correlation between DOG1 immunoexpression and risk groups of GISTs
Clinically malignant behavior is seen in 40-50% of intestinal GISTs and about 20-25% of gastric GISTs (1). We found high risk features, an indicator of aggressive behavior, in 58% of cases with a small intestine location and 27% of cases located in the stomach in our study.
Tumor size and mitotic rate have been accepted as the most reliable parameters by many authors for determining prognosis (1, 18, 32) . A tumor diameter less than 2 cm reduces the risk of progressive disease in all locations. A tumor larger than 5 cm in small intestine tumors and larger than 10 cm in gastric tumors was reported to be a poor prognostic factor when large series were investigated and classified according to localization in a more recent article of the same group of authors (19, 20) . Recurrent tumors and tumors with liver metastasis in our cases were larger; tumor diameter sizes were consistent with the literature findings.
The number of mitoses indicates active growth in the tumor. Five or fewer mitoses per 50 HPF is associated with low risk groups. However, it is especially emphasized that tumors with a mitotic index less than 10/50 HPF, but with other malignancy criteria can show malignant behavior too (27) . The average number of mitoses per 50 HPF was 15.25 (5-12-14-30 mitoses) in 4 of our cases with liver metastasis. Although there was a proportional relationship between malignant behavior and high mitotic index, recurrence occurred in one of the GISTs with 4 mitoses per 50 HPF localized in the small bowel, which was exceptional. This may be explained by the greater tumor size despite the low mitotic index. Invasion to surrounding tissues was present and the diameter was 10 cm in our small intestinal case with recurrence, although there were 4 mitoses per 50 HPF.
According to NIH (18) and AFIP (1) criteria (based on tumor location, size and mitoses), twenty (54%) of our 37 GIST cases were classified in the high risk group where malignant behavior is expected. A study presented at the 21st European Pathology Congress reported the classification of 1008 GIST cases gathered from 29 centers in Turkey as high risk in 54%, moderate in 19%, low risk in 21% and very low risk in 6% (33) . Another study with patients from 3 Turkish centers reported the distribution as high risk in 47%, moderate risk in 23%, low risk in 16% and very low risk in 3% (34) . The distribution of our cases according to risk group was consistent with the multi-center studies reflecting the general situation in our country.
Many histological criteria have been tested to predict the prognosis in GISTs, but most of them have not been adequately helpful. Lesions with small diameters (even those smaller than 2 cm) and very low mitotic rates have been reported to metastasize. Immunohistochemical studies have been conducted with cell proliferation markers with the aim of being more objective and identifying malignant behavior by many authors and was accepted as an important prognostic marker in terms of a higher than 10% positive result indicating a high proliferation index (18, 35, 36) . The Ki67 proliferation index was >10% in 37.8% of the GIST cases in our study. Evaluation according to risk group revealed a high proliferation index in 60% of the cases belonging to the high risk group, while this rate was 11.8% in other risk groups; the difference was significant (p<0.05).
Immunohistochemical studies are required in addition to routine HE examinations for the correct diagnosis of these special tumors that show similar morphological appearance and location to other mesenchymal tumors but have a totally different prognosis and treatment (37) . GISTs originate from the intestinal cells of Cajal, characterized usually by expression of the KIT protein, and are defined as c-Kit (CD117) immunopositive tumors. Expression of this marker plays a key role during diagnosis. CD117 immunohistochemical expression has been found with mutation analysis studies in PDGFRα-mutant and "wild type" GISTs, whereas CD117 can be negative in tumor tissue in c-Kit-mutant GISTs (1, 19, 22, 28) . GISTs have been reported to show diffuse and strong staining with CD117 at a rate of 65-100% in several publications (Table 6 ) (2-8,20-22,25,29-31,38,39). Positive reaction was seen for CD117 in all our cases and staining was diffuse, with strong staining found in 86% of the tumors in the study group.
CD34 was considered to be the most valuable marker for GIST diagnosis before identification of the CD117 antibody. CD34 positivity in GISTs varies between 40 and 82% in the literature (1, (18) (19) (20) 25, 28, 40, 41) . Positive immunreaction with CD34 was observed in 62% of our cases.
Immunohistochemical c-kit positivity was the gold standard in the verification of a GIST diagnosis and CD34 expression was accepted as a diagnostic supportive "marker" until recently. However, KIT negativity or uncertain CD117 expression in a significant number (~4-15%) of GISTs and especially PDGFRα mutant cases can cause difficulties in diagnosis (2, 3, 6) . Difficulties with optimization of KIT for IHC procedures can also cause false-positive and -negative results with the KIT marker (2) . In 2004, the hypothetical protein-encoding FLJ10261 gene was found to be expressed specifically in GISTs by West et al. (4) for the first time and was named DOG1 (1, 2, 16, 17) .
West et al. (4) stated that DOG1 (polyclonal) expression was found in 97.8% of GISTs by both immunohistochemistry and in situ hybridization, independent of the mutation status in their study. Similarly, 75-99% staining with the DOG1 antibody was found in GISTs in various studies that were subsequently conducted (2) (3) (4) (5) (6) (7) (8) . Instead of the polyclonal form of the DOG1 antibody, the K9, DOG1.1 and DOG1.3 monoclonal subtypes that have been reported to be more specific have Balkan Med J, Vol. 32, No. 4, 2015 been produced and used in various studies (2) (3) (4) (5) (6) (7) (8) 29, 31, 38) . As summarized in the article of Wong et al. (15) , the difference in positivity rates is thought to stem from the sensitivity features of the clone used. We mostly observed a diffuse and strong positive reaction with monoclonal DOG1 (clone SP31) antibody in 89% (33/37) of the GIST cases in our study. When we classified the cases as high risk and other groups, DOG1 positivity was 85% in the high risk group and 94% in the other groups. Although a mild decrease in the intensity and extent of DOG1 expression was found as the risk increased, it was not statistically significant (p>0.05).
An attempt has been made to define the most specific immunohistochemical panel for the diagnostic algorithm by comparing the expression rates with CD117 in almost all studies with DOG1 in the literature. The rate of DOG1 positivity was 20-100% in CD117 negative GIST cases in different studies, all of which reported that DOG1 should be added to the immunohistochemical panel in the diagnostic steps independent of the mutation status (2, (6) (7) (8) 29, 31, 38, 42) . In the present study, positivity with CD117 was provided by applying the immunohistochemical studies on multiple different paraffin blocks in those cases which could be negative for CD117 (focally and weak reaction). The DOG1 antibody can be useful, especially in high risk tumors exhibiting focal staining with CD117. Also, the staining pattern of CD117 in other tumors should be considered and final diagnosis can be made by including the DOG1 antibody in the immunohistochemical panel in the differential diagnosis.
As summarized in Table 6 , collective evaluation of the results of the series where CD117 and DOG1 antibodies were studied together (if we ignore the fact that these studies were performed under different laboratory conditions at different centers and by using different antibody clones) in GISTs (2) (3) (4) (6) (7) (8) (29) (30) (31) 38) revealed that the CD117 positivity rate was 91% and DOG1 positivity 93% in about three thousand GIST cases. DOG1 specificity was reported to be a little lower than, equal to or greater than CD117 specificity in different studies. The rate of DOG1 positivity in CD117 negative cases were reported in a wide range of 20-100% in the same studies. DOG1 positivity was found in 55% of the CD117 negative cases in these studies (Table 6) indicating that a little more than half of the CD117 negative cases could be differentiated with the DOG1 antibody.
Lopes et al. (7) found that the K9 clone had higher specificity by studying two different monoclonal clones (DOG1.1 and K9) of the DOG1 antibody in a GIST series of 668 cases. However, the DOG1 positivity rate varies between 37 and 100% in CD117 negative cases even in studies performed with the DOG1/K9 clone (2, 7, 8, 38) . The wide range of DOG1 positivity in CD117 negative cases in such series may be due to the low number of cases, differences among the DOG1 clones used or other unknown factors. We believe that more reliable results can be obtained with studies performed with the same DOG1 clone on a large series at a single center in the future.
PDGFRα gene mutation is a well-defined alternative oncogenic mechanism in GISTs where a classic c-Kit mutation is not found and is present in roughly 6.5% of GISTs. PDGFRα mutated GISTs are usually immunohistochemically CD117 negative tumors (42, 43) . Various results have been reported from studies investigating the significance of the PDGFRα immune marker in diagnosis (6, 21, (42) (43) (44) sion was not found. A diffuse and strong positive reaction was usually observed for PDGFRα in all GISTs in our study. However, the benefit of PDGFRα in routine immunohistochemical use was reported to be limited due to the optimization problems in the application of a PDGFRα antibody that can be commercially provided in particular and the inability to prevent intense background staining in more recent publications (6, 21) .
In conclusion, tumor diameter, mitosis, cytological atypia, necrosis, mucosal invasion and Ki67 index, all of which are accepted as histopathological parameters for progressive disease in the literature, were also found to be associated with high risk in our study. The results showed that immunohistochemical CD117 positivity is still a gold standard as a supportive finding in cases consistent with GIST in terms of tumor location site and histomorphological features. Antibody clone and laboratory conditions for immunohistochemical studies are important for the elimination of false CD117 negativity. However, the DOG1 antibody should be used as an alternative sensitive and specific marker in the immunohistochemical diagnostic panel in tumors with suspicious or negative staining for CD117. The use of PDGFRα as an auxiliary marker together with other antibodies may also be helpful.
